Loizidis, S.; Vogazianos, P.; Kordatou, Z.; Fotopoulos, G.; Orphanos, G.; Kyriakou, F.; Charalambous, H.
Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review. Curr. Oncol. 2025, 32, 612.
https://doi.org/10.3390/curroncol32110612
AMA Style
Loizidis S, Vogazianos P, Kordatou Z, Fotopoulos G, Orphanos G, Kyriakou F, Charalambous H.
Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review. Current Oncology. 2025; 32(11):612.
https://doi.org/10.3390/curroncol32110612
Chicago/Turabian Style
Loizidis, Sotiris, Paris Vogazianos, Zoe Kordatou, Georgios Fotopoulos, George Orphanos, Flora Kyriakou, and Haris Charalambous.
2025. "Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review" Current Oncology 32, no. 11: 612.
https://doi.org/10.3390/curroncol32110612
APA Style
Loizidis, S., Vogazianos, P., Kordatou, Z., Fotopoulos, G., Orphanos, G., Kyriakou, F., & Charalambous, H.
(2025). Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review. Current Oncology, 32(11), 612.
https://doi.org/10.3390/curroncol32110612
